Back to search results

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Hematologic Malignancy · Large B-cell Lymphoma · Acute Lymphoblastic Leukemia · Mantle Cell Lymphoma · Multiple Myeloma · Diffuse Large B Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cedars-Sinai Medical Center, Los Angeles, California, United States

    Contact: Study coordinator (Clinical Trial Recruitment Navigator) · GroupCancerTrialInformation@cshs.org · 310-423-2133
    John Chute, MD (Sub-investigator)
    Justin Darrah, MD (Sub-investigator)
    Noah Merin, MD, PhD (Sub-investigator)
    Ronald Paquette, MD (Sub-investigator)
    Robert Vescio, MD (Sub-investigator)
    Hannah Lee, MD (Sub-investigator)
    Akil Merchant, MD (Sub-investigator)
    David Oveisi, MD (Sub-investigator)
    Leslie Ballas, MD (Sub-investigator)
Study leads

  • Joshua Sasine, MD, PhD

    Principal Investigator

    Cedars-Sinai Medical Center

View source on ClinicalTrials.gov(opens in a new tab)